GINTS IVUSKANS | AFP | Getty Images
Last month, the European Union launched legal action against the Anglo-Swedish pharmaceutical company over complaints that AstraZeneca failed to meet its delivery targets with the block. AstraZeneca has denied the charges, saying it will defend itself firmly in court.
“At the moment, it’s no,” Didier Reynders, EU justice commissioner, told CNBC when asked if the committee had any plans for a new contract with AstraZeneca. “It’s absurd to think of a new contract,” he added.
“It is not a problem with the quality of the vaccine. We said it is a very high quality vaccine so we have no problem using the AstraZeneca vaccines, ”Reynders said, explaining that the problem was the lack. deliveries.
The EU expected 120 million doses of AstraZeneca in the first quarter, but has only received around 30 million doses.
AstraZeneca said poor performance issues at European factories have caused delays in distribution. The company said in a statement in March that it expected to deliver 100 million doses to the EU by the end of the second quarter – below EU expectations for 300 million doses during this period.
Earlier this month, EU Internal Market Commissioner Thierry Breton said the EU had not placed any new orders with AstraZeneca beyond June.
“In the first quarter we didn’t get what was in the contract and for the second quarter it will be the same,” Reynders told CNBC.
The lawyer said Wednesday in a Belgian court that AstraZeneca had “diverted” doses to other customers, according to Reuters.
Despite a bumpy initial vaccination rollout, the EU appears to be catching up with other parts of the world.
European Commission President Ursula von der Leyen said on Tuesday that “by the end of the week, more than 300 million doses of vaccine will have been delivered to member states”.
“We are therefore on the right track to achieve our goal of delivering enough doses to vaccinate 70% of the adult population of the European Union by the end of July,” she added.